May 31, 2019
For patients with newly diagnosed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone is associated with a reduced risk for disease progression or death, according to a study published in the May 30 issue of the New England Journal of Medicine. Thierry Facon, M.D., from the University of Lille in France, and colleagues...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand